Lercanidipine Actavis

Lercanidipine, the active ingredient in Lercanidipine Actavis, is a calcium channel blocker presented as a tablet for oral use. It is used to treat hypertension in adult patients. GNH USA supplies Lercanidipine Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium channel blocker indicated for the management of high blood pressure. - Hypertension: lowers systolic and diastolic blood pressure, helping to reduce the risk of cardiovascular events. - Essential hypertension: provides sustained vasodilation to control chronic elevated blood pressure. - Isolated systolic hypertension: improves arterial compliance to manage elevated systolic readings.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: sensation of warmth and redness. - Peripheral edema: swelling of ankles or feet. - Dizziness: especially on standing. - Tachycardia: increased heart rate. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Myocardial infarction: rare cardiac event. - Angioedema: swelling of face, lips, or throat. - Hepatic injury: abnormal liver function tests. - Severe bradycardia: markedly slow heart rate. - Anaphylactic reaction: life‑threatening allergic response.

Patients should be evaluated for safety before initiating therapy and monitored during treatment. - Blood pressure monitoring: check regularly to ensure therapeutic targets are met. - Liver function assessment: evaluate before starting and during prolonged use. - Concomitant antihypertensives: adjust doses to avoid excessive hypotension. - Elderly patients: start at lower doses and monitor for orthostatic effects. - Discontinuation: avoid abrupt cessation; taper if clinically indicated. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels and risk of hypotension. - Combined use with other potent antihypertensives (e.g., ACE inhibitors, ARBs): can cause additive blood pressure lowering.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug exposure and effectiveness. - Grapefruit juice: can modestly increase lercanidipine concentrations. - Diuretics: may enhance orthostatic hypotension. - Beta‑blockers: may require dose adjustments to maintain hemodynamic stability.